The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown. We retrospectively analyzed data from breast cancer patients who began treatment with regimens of lapatinib plus capecitabine (LC or LX) or trastuzumab beyond progression (TBP) at eight hospitals between May 2010 and October 2017. Among 554 patients who had developed resistance to trastuzumab, the median PFS (progression free survival) was 6.77 months in the LX group compared with 5.6 months in the TBP group (hazard ratio 0.804; 95% CI, 0.67 to 0.96; P = 0.019). The central nervous system progression rate during treatment was 5.9% in the LX group and 12.5% in the TBP group (P = 0.018). The combination of lapatinib and capecitabine showed a prolonged PFS relative to TBP in patients who had progressed on trastuzumab.

中文翻译：

---

拉帕替尼联合卡培他滨与曲妥珠单抗耐药的乳腺癌患者继续使用曲妥珠单抗的回顾性研究

尚不知道拉帕替尼联合卡培他滨（LC或LX）与曲妥珠单抗联合化疗在对曲妥珠单抗有抵抗力的HER阳性转移性乳腺癌患者中的疗效和安全性。我们回顾性分析了2010年5月至2017年10月间在八家医院开始接受拉帕替尼联合卡培他滨（LC或LX）或曲妥珠单抗治疗（超过进展）（TBP）方案的乳腺癌患者的数据。在554名对曲妥珠单抗产生耐药性的患者中， LX组的中位PFS（无进展生存期）为6.77个月，而TBP组为5.6个月（危险比0.804； 95％CI为0.67至0.96； P = 0.019）。LX组治疗期间中枢神经系统进展率为5.9％，TBP组为12.5％（P = 0.018）。